Refine
Document Type
- Doctoral Thesis (20)
Has Fulltext
- yes (20)
Is part of the Bibliography
- no (20)
Keywords
- Antigen carrier (1)
- Autophagy (1)
- Binding Kinetics (1)
- Binding kinetic (1)
- DDR (1)
- Flavin homeostasis (1)
- Kinase (1)
- Kinase Inhibitors (1)
- Kinase inhibitors (1)
- M1 Ubiquitination (1)
Institute
- Biochemie, Chemie und Pharmazie (17)
- Biochemie und Chemie (2)
- Pharmazie (2)
Guanosine triphosphate (GTP) cyclohydrolase I (GCH1) catalyzes the conversion of GTP to dihydroneopterin triphosphate (H2NTP), the initiating step in the biosynthesis of tetrahydrobiopterin (BH4). Besides other roles, BH4 functions as cofactor in neurotransmitter biosynthesis. The BH4 biosynthetic pathway and GCH1 have been identified as promising targets to treat pain disorders in patients. The function of mammalian GCH1s is regulated by a metabolic sensing mechanism involving a regulator protein, GCH1 feedback regulatory protein (GFRP). GFRP binds to GCH1 to form inhibited or activated complexes dependent on availability of cofactor ligands, BH4 and phenylalanine, respectively. We determined high-resolution structures of human GCH1−GFRP complexes by cryoelectron microscopy (cryo-EM). Cryo-EM revealed structural flexibility of specific and relevant surface lining loops, which previously was not detected by X-ray crystallography due to crystal packing effects. Further, we studied allosteric regulation of isolated GCH1 by X-ray crystallography. Using the combined structural information, we are able to obtain a comprehensive picture of the mechanism of allosteric regulation. Local rearrangements in the allosteric pocket upon BH4 binding result in drastic changes in the quaternary structure of the enzyme, leading to a more compact, tense form of the inhibited protein, and translocate to the active site, leading to an open, more flexible structure of its surroundings. Inhibition of the enzymatic activity is not a result of hindrance of substrate binding, but rather a consequence of accelerated substrate binding kinetics as shown by saturation transfer difference NMR (STD-NMR) and site-directed mutagenesis. We propose a dissociation rate controlled mechanism of allosteric, noncompetitive inhibition.
The aim of this work was to establish a new way of predicting novel dual active compounds by combining classical fingerprint representation with state-of-the-art machine learning algorithms. Advantages and disadvantages of the applied 2D- and 3D-fingerprints were investigated. Further, the impact of various machine learning algorithms was analyzed. The new method developed in this work was used to predict compounds, which inhibit two different targets (LTA4H and sEH) involved in the same disease pattern (inflammation). The development of multitarget drugs has become more important in recent years. Many widespread diseases like metabolic syndrome, or cancer are of a multifactorial nature, which makes them hard to be treated effectively with a single drug. The new in silico method presented in this work can help to accelerate the design and development of multitarget drugs, saving time and efforts.
The nowadays readily available access to a large number of 3D-structures of biological targets and published activity data of millions of synthesized compounds enabled this study and was used as a starting point for this work. Four different data sets were compiled (crystalized ligands from the PDB, active and inactive compounds from ChEMBL23, newly designed compounds using a combinatorial library). Those data sets were collected and processed using an automated KNIME workflow. This automation has the advantage of allowing easy change and update of compound sources and adapted processing ways.
In a next step, the compounds from the compiled data sets were represented using a variety of well-established 2D- and 3D-fingerprints (PLIF, AtomPair, Morgan, FeatMorgan, MACCS). All those fingerprints share the same underlying bit string scheme but vary in the way they describe the molecular structure. Especially the difference between 2D- and 3D-fingerprints was investigated. 2D-fingerprints are solely based on ligand information. 3D-fingerprints, on the other hand, are based on X-ray structure information of protein-ligand complexes. One major difference between 2D- and 3D-fingerprints usage is the need for a 3D-conformation (pose) of the compound in the targets of interest when using 3D-fingerprints. This additional step is time-consuming and brings further uncertainties to the method.
Based on the calculated fingerprints state-of-the-art machine learning algorithms (SVC, RF, XGB and ADA) were used to predict novel dual active compounds. The models were evaluated by 10-fold cross validation and accuracy as the primary measure of model performance was maximized. Second, individual parameters of the four machine learning algorithms were optimized in a grid search to achieve maximal accuracy using the optimized partitioning scheme. Overall accuracies, regardless of fingerprint and machine learning algorithm, are slightly better for LTA4H than for sEH.
The goal to predict dual active compounds was realized by comparing the set of predicted to be active compounds for LTA4H and sEH. For the 3D-fingerprint PLIF the machine learning algorithm Random Forest was chosen, from which compounds for synthesis and testing were selected. Of 115 predicted to be active compounds, six compounds were cherry picked. Two compounds showed very good/moderate dual inhibitory activity. Of the 2D-fingerprints, the AtomPair fingerprint in combination with the machine learning algorithm Random Forest was chosen from which compounds were selected for synthesis and testing. 116 compounds were predicted to be dual active against LTA4H and sEH. One of those compounds showed good dual inhibitory activity.
In this work it was possible to show advantages and disadvantages of using 2D- and 3D-fingerprints in combination with machine learning algorithms. Both strategies (2D: ligand-based, 3D: structure-based) lead to the prediction of novel dual active compounds with moderate to very good inhibitory activity. The method developed in this work is able to predict dual active compounds with very good inhibitory activity and novel (previously unknown) scaffolds inhibiting the targets LTA4H and sEH. This contribution to in silico drug design is promising and can be used for the prediction of novel dual active compounds. Those compounds can further be optimized regarding binding affinity, solubility and further pharmacological and physicochemical properties.
The dodecin of Mycobacterium tuberculosis : biological function and biotechnical applications
(2020)
Biological Function of Bacterial Dodecins
In this thesis, the dodecins of Mycobacterium tuberculosis (MtDod), Streptomyces coelicolor (ScDod) and Streptomyces davaonensis (SdDod) were studied. Kinetic measurements of the flavin binding of MtDod revealed that the dodecin binding pocket is filled in two distinct steps, for which a kinetic model then was established and verified by experimental data. The analysis with the two-step model showed that the unique binding pocket of dodecins allows them to bind excessive amounts of flavins, while at low flavin concentrations, flavin is released and only weakly bound. This function of flavin buffering prevents accumulation of free oxidised flavins and therefore helps to keep the redox balance of the cell and prevents potential cell damage caused by excessive free flavins. To further gain insights into the role of bacterial dodecins, the effect of knocking out the dodecin encoding gene in S. davaonensis was analysed. The knockout strain showed increased concentrations of various stress related metabolites, indicating that without dodecin the cellular balance is disrupted, which supports the role of dodecins as a flavin homeostasis factor.
With a self-designed affinity measurement method based on the temperature dependent dissociation of the dodecin:flavin complex, which allowed parallel screening of multiple conditions, it was shown that MtDod, ScDod and SdDod have much higher affinities towards FMN and FAD under acidic conditions. Under these conditions, the three dodecins might function as a FMN storage. M. tuberculosis encounters multiple acidic environments during its infection cycle of humans and can adopt a state of dormancy. During recovery from the dormant state, a flavin storage might be beneficial. For some Streptomyces species it was reported that the formed spores are slightly acidic and therefore ScDod and SdDod could function as flavin storages for the spores. Further details on the flavin binding mechanism of MtDod were revealed by a mutagenesis study, identifying the importance of a histidine residue at the fourth position of the protein sequence for flavin binding, but contrary to expectations, this residue seems only to be partly involved in the pH related affinity shift.
The data, reported in this thesis, demonstrates that bacterial dodecins likely function as flavin homeostasis factors, which allow overall higher flavin pools in the cell without disrupting the cellular balance. Further, the reported acid-dependent increase in binding affinity suggests that under certain conditions bacterial dodecins can also function as a flavin storage system.
Application of the Dodecin of M. tuberculosis
In this thesis, the stability of MtDod, ScDod SdDod and HsDod was analysed to find a suitable dodecin for the use as a carrier/scaffold. Therefore, a method to easily measure the stability of dodecins was designed, which measures the ability of the dodecamer to rebind flavins after a heating phase with stepwise increasing temperatures. Using this assay and testing the stability against detergents by SDS PAGE, showed that the dodecamer of MtDod possesses an excellent stability against a vast array of conditions, like temperatures above 95 °C, low pH and about 2% SDS. By solving the crystal structure of ScDod and SdDod, the latter forming a less stable dodecamer, combined with a mutagenesis study, the importance of a specific salt bridge for dodecamer stability was revealed and might be helpful to find further highly stable dodecins.
In addition to the intrinsic high stability of the MtDod dodecamer, also the robustness of the fold was tested by creating diverse MtDod fusion constructs and producing them in Escherichia coli. Here it was shown that MtDod easily tolerates the attachment of proteins up to 4-times of its own size and that both termini can be modified without affecting the dodecamer noticeably. Further, it was shown that MtDod and many MtDod fusion constructs could be purified in high yields via a protocol based on the removal of E. coli proteins through heat denaturation and subsequent centrifugation. In a case study, by fusing diverse antigens from mostly human proteins to MtDod and using these constructs to produce antibodies in rabbits, it was demonstrated that MtDod is immunogenic and presents the attached antigens to the immune system.
The here reported properties of MtDod and to a lesser degree of other bacterial dodecins, show that bacterial dodecins are a valuable addition to the pool of scaffold and carrier proteins and have great potential as antigen carriers.
The simultaneous inhibition of HDACs and BET proteins has shown promising anti-proliferative effects against different cancer types, including the difficult to treat pancreatic cancer. In this work, the strategy of concurrently targeting HDACs and BET proteins was pursued by developing different types of dual inhibitors.
By developing a novel scaffold that selectively inhibits HDAC1/2 together with BET proteins in cells, an effective tool for the investigation of pancreatic cancer, and other diseases which are sensitive to epigenetic processes, was created. The compound’s small size further gives the opportunity to further develop the inhibitor towards optimized pharmacokinetic properties, potentially resulting in a drug for cancer treatment.
A second novel approach that was pursued, was the development of a small-molecule degrader, targeting HDACs and BET proteins. Through synthesizing a variety of different molecules, a compound that was capable of lowering BRD4 levels and, at the same time, increasing histone acetylation was developed. While additional mechanistic investigations are needed to verify the degradation, the potent antiproliferative effects in pancreatic cancer cells encourage further studies following this alternative new strategy.
This thesis comprises the usage of two commonly known hinge-binding moieties in drug discovery. First, the quinazoline scaffold of gefitinib (5) was utilized in a macrocyclization strategy to introduce selectivity. In general, the quinazoline hinge-binding moiety is a commonly used scaffold which can be found in 14% of approved kinase inhibitors. The most familiar applications are EGFR inhibitors such as gefitinib (5), erlotinib (6), afatinib, or dacomitinib for the treatment of NSCLC. But other kinases like CDK2, CDK4, or p38 are reported targets as well.
The N-phenylquinazolin-4-amine moiety of gefitinib (5) was conserved however, the residues at the aromatic ring in the linker were modified, the residue targeting the solvent-exposed region was varied, and the linker at the C6 position of the quinazoline was adjusted to enable the macrocyclization. An overview of the structural modifications is shown in Figure 35A.
Kinome-wide screening of gefitinib (5) revealed several off-targets besides EGFR (Figure 35B), making it an excellent starting point for a macrocyclization strategy. Introducing a linker to the N phenylquinazoline-4-amine scaffold and retaining the residues on the aromatic ring as well as the methoxy group targeting the solvent-exposed region improved the selectivity profile and the efficacy towards EGFR WT and its mutants. Truncation of the linker moiety led to the mutant selective macrocycle 26f with an excellent kinome-wide selectivity profile (Figure 35B). An inhibitor that is effective on EGFR mutations while ineffective on the EGFR WT could represent an enhancement of patient treatment, as it potentially causes less side effects. Further studies could determine the effect of the most promising macrocycles in lung cancer cell lines. Additionally, the pharmacokinetic properties could be optimized, e.g. by introducing solubilizing groups, targeting the solvent-exposed region.
The second scaffold comprises the 3-aminopyrazole-based hinge-binding moiety. It is a privileged scaffold in medicinal chemistry for the development of kinase inhibitors. Previous publications report the anti-proliferative and anti-cancer potential of pyrazole-based molecules. They play a crucial role in the treatment of various diseases and cancer types like inflammation disorders, lymphoma, or breast cancer. This scaffold can be found e.g. in the aurora kinase inhibitor tozasertib or in the promiscuous kinase inhibitor 23, published by Statsuk et. al. Rescreening compound 23 in a comprehensive kinase panel against 468 human protein kinases confirmed the unselective behavior with a selectivity score of S35 = 0.56 (Figure 36B), making it a great starting point for further optimizations. The N-(1H-pyrazol-3-yl)pyrimidin-4-amine scaffold was conserved however, the residues targeting the solvent-exposed region were varied and different linkers were attached.
The introduction of different residues at the pyrazole dramatically influenced the selectivity profile of the desired kinases. Ester moieties caused to a favorable combination of selectivity and potency towards the kinase of interest CDK16. The removal of additional residues at the pyrimidine, targeting the solvent-exposed region, increased the efficiency towards CDK16. Further optimization led to the highly potent and selective CDK16 inhibitor 98d (IC50 = 33 nM). NanoBRETTM screening against the complete CDK family revealed a preferred inhibition of the PCTAIRE and PFTAIRE subfamily with cellular IC50 values of 20 nM – 120 nM and 50 nM – 180 nM, respectively. A FUCCI cell cycle assay and viability assessment of 98d confirmed previously published results, reporting a G2/M cell cycle arrest followed by apoptosis and accumulation of p27 through knockout of CDK16 in SCC cells. Consequently, further studies could evaluate the anti-tumor activity of 98d in SCC and NSCLC or elucidate the effect of 98d in AMPK-related macroautophagy. 98d represents a novel tool compound to investigate the understudied kinases of the PCTAIRE family and enable to enlighten the biological role of those kinases.
Macrocyclization of the N-(1H-pyrazol-3-yl)pyrimidin-4-amine core resulted in the selective BMPR2 inhibitor 110a. It showed a good binding affinity towards BMPR2 with a KD value of 205 nM as well as a good potency with an IC50 value of 506 nM. A comprehensive selectivity screen against 468 kinases revealed an excellent selectivity profile with S35 = 0.01. As no BMPR2 inhibitors have been published so far, 110a represents a novel compound that may provide further insights into the canonical BMP pathway, noncanonical signaling, or its impact on BMPR2-associated diseases like PAH.
The introduction of additional residues targeting the solvent-exposed region shifted the selectivity towards the MST kinases. The exchange from the pyrimidine to a quinazoline moiety resulted in the highly potent and selective macrocyclic MST3 inhibitor 113c. NanoBRETTM measurements demonstrated the preferred inhibition of MST3 with IC50 values of 210 nM and 30 nM for intact and lysed cells, respectively. A weaker activity could be seen for MST4 with 1.8 µM and 510 nM, while MST1 and MST2 were not affected. To date, no selective MST3 inhibitors have been published, making 113c a valuable tool compound for further functional studies. As MST3 is influencing the cell cycle progression, 113c could be tested in a further cell cycle assay to elucidate the inhibitory effect of 113c on MST3 and consequently on the cell cycle. Furthermore, the anti-tumor activity of 113c in breast cancer could be determined, as Madsen et. al. reported a high MST3 and MST4 activity triggered by FAM40B mutations.
Die Beteiligung an Schlüsselfunktionen in zellulären Signalwegen macht Kinasen zu einem vielversprechenden Ansatzpunkt in der Wirkstoffentwicklung bei verschiedenen menschlichen Erkrankungen wie z.B. Krebs oder auch Autoimmun- und Entzündungskrankheiten. Die Prävention von post-translationalen Modifikationen durch Phosphorylierung und somit die Regulierung der nachgeschalteten Signalwege ist das Ziel von Kinaseinhibitoren. Die katalytische Aktivität von Kinasen ist abhängig von ATP, welches im hochkonservierten aktiven Zentrum bindet. Bedingt durch diese kinomweite hohe Konservierung stellt die Entwicklung von hoch selektiven ATP-mimetischen Inhibitoren eine Herausforderung dar. Typische ATP-Mimetika sind flach und die oft hydrophoben Moleküle weisen meist eine große Zahl an frei rotierbaren Bindungen auf. Um das aus dieser Flexibilität hervorgehende Problem der teils mangelnden Selektivität zu umgehen, kann eine bioaktive Konformation des Inhibitors durch Makrozyklisierung fixiert werden. Als Konsequenz dieser konformationellen Einschränkung können die entropischen Kosten während des Bindens reduziert werden und folglich zu einer gesteigerten Affinität gegenüber der Kinase führen.
Der Grundstein dieser Arbeit war der makrozyklische Pyrazolo[1,5-a]pyrimidin basierte FLT3 Kinaseinhibitor ODS2004070 (37). Im Rahmen eines kinomweiten Screenings konnten hohe Affinitäten zu verschiedensten Kinasen detektiert werden, was 37 zu einer guten Leitstruktur für das Design von potenten und selektiven Kinaseinhibitoren machte. Im Rahmen dieser Arbeit blieb das literaturbekannte Pyrazolo[1,5-a]pyrimidin basierte ATP-mimetische Bindemotiv sowie das makrozyklische Grundgerüst 37 bis auf einige wenige Variation unverändert.
Strukturelle Optimierungen zur Fokussierung der Selektivität wurden am sekundären Amin zwischen Bindemotiv und Linker als auch über die freie Carbonsäure durchgeführt. Mit einer Anzahl von mehr als 430 identifizierten Phosphorylierungsstellen ist die pleiotropisch und konstitutiv aktive Casein Kinase 2 (CK2) an verschiedensten zellulären Prozessen wie dem Verlauf des Zellzyklus, der Apoptose oder der Transkription regulatorisch beteiligt. Die Fehlregulation von CK2 wird häufig mit der Pathologie von Krankheiten wie zum Beispiel Krebs assoziiert, was CK2 zu einem vielversprechenden Ziel klinischer Untersuchungen macht.
Im Rahmen des CK2-Projekts war es möglich, durch spezifische Modifikationen an 37, die hoch selektiven und potenten CK2-Inhibitoren 47 und 60 zu entwickeln. Ebenfalls gezeigt wurde, dass kleine strukturelle Veränderungen, wie z.B. Makrozyklisierung, einen signifikanten Effekt auf Selektivität und Potenz des Inhibitors haben kann.
Weiter Untersuchungen der Verbindungen lenkten den Fokus weiterer Arbeiten u.a. auf die Serin/Threonin Kinase 17A (STK17A) oder auch death-associated protein kinase-related apoptosis-inducing protein kinase 1 (DRAK1) genannt. Sie ist Teil der DAPK Familie und gehört zusammen mit anderen Kinasen zu den weniger erforschten Kinasen. Bis heute ist nicht viel über ihre zellulären Funktionen und die Beteiligung an pathophysiologischen Prozessen bekannt. Berichtet wurde jedoch eine Überexpression in verschiedenen Formen von Hirntumoren des zentralen Nervensystems (Gliom). Strukturelle Modifikationen, unter Erhalt des makrozyklischen Grundgerüsts 37, führten zu dem hoch selektiven und potenten DRAK1 Inhibitor 121, der alle Kriterien für eine chemical probe Verbindung erfüllt.
Ein weiteres Ziel dieser Arbeit war die AP-2-assoziierte Protein Kinase 1 (AAK1) aus der NAK Familie, bestehend aus AAK1, BIKE und GAK. Sie ist als potenzielles therapeutisches Ziel für viele verschieden Krankheiten wie z.B. neuropathische Schmerzen, Schizophrenie und Parkinson identifiziert. Durch die Regulierung der Clathrin-mediierten Endozytose ist AAK1 an intrazellulären Bewegungen verschiedener nicht zusammenhängenden RNS- und DNSViren, wie beispielsweise HCV, DENV oder EBOV, beteiligt. Ebenfalls berichtet wurde eine mögliche Assoziation mit dem SARS-CoV-2 Virus, was das Interesse an neuen selektiven AAK1 Inhibitoren verstärkte. Die Entwicklung der hochpotenten und selektiven AAK1 Inhibitoren 61 und 63 basierte ebenfalls auf dem makrozyklischen Grundgerüst 37, das bereits im CK2- und DRAK1-Projekt verwendet wurde.
Zusammenfassend lässt sich sagen, dass es im Rahmen dieser Arbeit gelungen ist, ausgehend von einem höchst unselektiven makrozyklischen Grundgerüst, hochpotente und selektive Kinaseinhibitoren für CK2, DRAK1 und AAK1 zu entwickeln und zu charakterisieren. Im Zuge von Untersuchungen verschiedener Struktur-Wirkungsbeziehungen wurde gezeigt, dass es durch geringfügige strukturelle Modifikationen möglich ist, die kinomweite Selektivität zu variieren und auf eine Kinase zu fokussieren. Diese Arbeit brachte nicht nur die erwähnten Inhibitoren hervor, sondern bildet auch die Grundlage für weitere Projekte zur Entwicklung von hoch potenten und selektiven Verbindungen als potenzielle chemische Werkzeuge für den Einsatz in der Forschung.
The p38α mitogen-activated protein kinase (MAPK) is activated through stress stimuli such as heat shock or hypoxia. In the nucleus, p38α modulates the activity of other kinases and transcription factors, a process that regulates the expression of specific target genes, most importantly pro-inflammatory cytokines. Dysregulation of p38α therefore plays a major role in the development of inflammatory diseases such as rheumatoid arthritis. Despite many years of intensive research, no p38 small-molecule inhibitors have been approved yet. Several inhibitor design strategies have been reported, leading to >100-fold selective compounds for α/β over the γ and δ isoforms. Achieving such a selectivity among the two structurally most related α and β isoforms, however, remains a challenging task. Targeting an inactive DFG-out conformation offers another strategy for the development of potent kinase inhibitors (type-II), exemplified by the BCR/ABL-inhibitor Imatinib. Achieving selectivity with type-II binders is challenging, because many kinases can adopt an inactive DFG-out conformation. This is exemplified by the p38 type-II inhibitor BIRB-796, which exhibits picomolar on-target affinity but only a poor kinome-wide selectivity. A potent and selective type-II chemical probe for p38α/β was still lacking at the start of this thesis.
The promising hit VPC-00628, was chosen for a combinatorial synthetic approach to develop a type-II chemical probe. The studies covered the optimization of the hinge-binding head group, the hydrophobic region I and the DFG-out deep pocket of the lead compound VPC-00628. Selectivity for the p38α and p38β isoforms was monitored during the optimization process, which identified several inhibitors with favorable isoform selectivity, providing valuable insights into the potential of isoform-selective inhibitor design for p38. A potent and highly selective p38 MAPK probe (SR-318) was discovered, which showed IC50 values in the low nanomolar range in HEK293T cells. An unusual P-loop conformation induced upon binding of SR-318 to p38α contributed most likely to the impressive selectivity profile within the kinome that surpassed both the parent compound and BIRB-796. A negative control compound, SR-321, was developed, to distinguish between on-target effects and non-specific effects due to cross-reactivity with other cellular proteins. Studies of the metabolic stability in human liver microsomes revealed a high stability of the compounds, with only a small amount of metabolites formed over several hours. Compound SR-318 also exhibited a good in vitro efficacy, quantitatively reducing the LPS-stimulated TNF-α release in whole blood. Taken together, SR-318 is a highly potent and selective type-II p38α/β chemical probe, which will help to gain a better understanding of the catalytic and non-catalytic functions of these key signaling kinases in physiology and pathology.
The next studies focused on the exploration of the highly dynamic allosteric back pocket of p38 MAPK, and allosteric BIRB-796 derived compounds for targeting the αC- and DFG-out pockets were synthesized. Kinase activities of allosteric pyrazole-urea fragments were analyzed against a comprehensive set of 47 diverse kinases by differential scanning fluorimetry (DSF), revealing that BIRB-796 off-targets remain a problem when targeting this back-pocket binding motif. Revisiting the recently published compound MCP-081, which combines the allosteric part of BIRB-796 with the active-site directed part of VPC-00628, showed that it displays a clean selectivity profile in our kinase panel. Because the potency of MCP-081 was slightly reduced compared with VPC-00628 and the allosteric tert-butyl pyrazole moiety seemed suboptimal, a set of VPC-00628 derivatives for targeting the αC-out pocket region was synthesized. Through structure-guided extension of the terminal amide of VPC-00628 toward this allosteric site, the potent and selective compound SR-43 was developed, which showed excellent cellular activity on p38 MAPK in NanoBRETTM assays (IC50 [p38α/β] = 14.0 ± 0.1/ 16.8 ± 0.1 nM). SR-43 showed a dose-dependent inhibition of activating phosphorylation of p38 in HCT-15 cells as well as inhibition of phosphorylation of p38 downstream substrates MK2 and Hsp27. In addition, SR-43 induced an anti-inflammatory response by blocking TNF-α release in whole blood and displayed a high metabolic stability. Selectivity profiling of SR-43 revealed a narrow selectivity for additional targets such as the discoidin domain receptor kinases (DDR1/2). DDR kinases play a central role in fibrotic disorders, such as renal and pulmonale fibrosis, atherosclerosis and different forms of cancer. Since selective and potent inhibitors for these important therapeutic targets are largely lacking and the existing inhibitors are of low scaffold diversity, the next study focused on the optimization of SR-43 toward DDR1/2 kinase inhibition. The synthetic work covered the optimization of the hinge-binding head group and the allosteric part of SR-43 toward DDR1/2 kinase inhibition. These studies provided novel insights into the P-loop folding process of p38 MAPK and how targeting of non-conserved amino acids affects inhibitor selectivity. Importantly, they led to the development of a selective dual DDR/p38 inhibitor probe, SR-302, with picomolar affinity for DDR2. SR-302 was efficient in vitro and showed a destabilizing effect on the surface adhesion protein E-cadherin in epithelial cells. In summary, SR-302 and its negative control SR-301 provide a valuable tool set for studying the phenotypic effects of DDR1/2 signaling, e.g., in cancer cell lines.
Die Autophagie ist ein in Eukaryonten evolutionär konservierter Prozess, bei dem es zu einem lysosomalen Abbau von cytosolischen Bestandteilen kommt. Die dabei entstehenden biochemischen Bausteine stehen anschließend erneut zum Aufbau benötigter Strukturen zur Verfügung. Verschiedene Stimuli, wie beispielsweise Nährstoffmangel, können die Aktivität der Autophagie erhöhen und ermöglicht Zellen dadurch die Aufrechterhaltung der Zellhomöostase, selbst unter Stressbedingungen. Im Verlauf der Autophagie bildet sich eine tassenförmige Doppelmembran-Struktur, das sogenannte Phagophor. Dieses wächst, um das abzubauende Material zu umschließen und wird dabei von sogenannten Atg-Proteinen (autophagy-related genes) prozessiert. Nach der Schließung spricht man vom Autophagosom, welches letztlich mit einem Lysosom verschmilzt und das Autophagolysosom bildet, welches wiederum die eingeschlossenen Bestandteile zerlegt und die recycelten Bausteine freigibt. Die einzelnen Schritte während der Autophagie sind hochgradig durch die Atg-Proteine reguliert. Eines dieser Atg-Proteine, das Atg8, ist an einigen entscheidenden Schritten wie dem Phagophor-Wachstum, der Autophagosom-Reifung sowie der Schließung beteiligt. Während es in Hefen nur ein einziges Atg8-Protein gibt, so zeigt sich in höheren Eukaryonten meist eine gewisse Diversität. So codiert beispielsweise das humane Genom mindestens sechs Atg8-Homologe. Neben den drei Proteinen der LC3-Familie (A, B, C) zählen auch GABARAP, GABARAPL1 und GABARAPL2 dazu. Die Gründe für diese Diversität sind noch nicht vollständig aufgeklärt, weshalb es wichtig ist, möglichst selektive Modulatoren zu entwickeln, um so die Aufgaben der einzelnen Homologen entschlüsseln zu können. Eine weitere wichtige Aufgabe übernimmt Atg8 beim Binden des abzubauenden Materials über sogenannte Autophagie-Rezeptoren, wie beispielsweise p62. Der Bindevorgang beruht dabei auf der Interaktion von p62 mit ubiquitinierten Zellbestandteilen auf der einen Seite und der Interaktion zwischen p62 und LC3 auf der anderen Seite. Letztgenannte beruht auf dem Binden des LIR-Motivs (LC3-interagierende Region) von p62 an die LDS (LIR-docking site) des LC3-Proteins. Das LIR-Motiv zeichnet sich durch Aminosäure-Sequenz D-D-D-W/F/Y-X1-X2-L/I/V aus. Währende die aromatische Seitenkette (W/F/Y) die hydrophobe Tasche 1 (HP1) der LDS besetzt, ragt die aliphatische Seitenkette (L/I/V) in die HP2 hinein. Damit sollte es möglich sein, die LIR-LC3-Interaktion, durch das Besetzen der LDS zu stören bzw. zu inhibieren. Solche Inhibitoren könnten zum einen der weiteren Aufklärung der Prozesse, an denen die Autophagie beteiligt ist, dienen, zum anderen jedoch auch die Untersuchung fehlerhafter Autophagie ermöglichen. Ausgangspunkt für diese Arbeit stellt die Verbindung Novobiocin dar, die im Rahmen eines Mitteldurchsatz-Screenings als potenzieller Inhibitor der LIR-LC3-Interaktion identifiziert und mittels ITC, TSA und 1H-15N-HSQC verifiziert werden konnte. Die Struktur des Novobiocins setzt sich aus dem 3-Amino-4-hydroxy-8-methylcoumarin-Kern, der über eine Amidbindung an 3-iso-Prenyl-4-Hydroxybenzoesäure gebunden ist, sowie einer O-glykosidischen Bindung in Position C7 des Coumarins mit L-Noviose zusammen. Da es sich bei Novobiocin (XL6) um ein verhältnismäßig komplexes Molekül handelt, wurde der Einfluss einzelner funktionellen Gruppen des Moleküls auf die Bindungsaffinität hin untersucht. Hierfür wurden Synthesestrategien sowohl für die Coumarin-Gerüste als auch verschiedene Benzoesäuren entwickelt. Die erhaltenen Verbindungen wurden mittels ITC und TSA untersucht. Dabei wurde die Verbindung MH507 als geeigneter Ausgangspunkt für die Untersuchung der Struktur-Aktivitätsbeziehungen (SAR) bezüglich der Benzamid-Seite identifiziert. Im Rahmen einer ersten SAR-Untersuchung wurden neben verschiedenen 3-Alkyl-benzoesäuren, auch verschiedene divalente Isostere (-O-, -S-, -NHSO2-) der benzylischen Methylengruppe synthetisiert. Diese, sowie kommerzielle Aminosäuren, wurden mit 3-Amino-4,7-dihydroxycoumarin zu den entsprechenden Endverbindungen gekuppelt. Ergänzend dazu wurden auch eine Verbindung mit umgekehrter Konstitution der Amidbindung dargestellt, um den Einfluss der Reihenfolge zu verifizieren. In einer weiteren SAR-Studie wurden Derivate synthetisiert, die zusätzlich eine Funktionalisierung am C7 des Coumarin-Gerüstes über Amidkupplung, Sulfonamid-Bildung bzw. Suzuki-Reaktion erlauben und somit eine Interaktion mit der HP1 ermöglichen könnten. Dafür wurde eine weitere Synthesestrategie zur Darstellung von 7-Nitro- bzw. 7-Brom-3-amino-4-hydroxycoumarinen ausgearbeitet und eine Reihe von Endverbindungen dargestellt. Neben den Coumarin-Derivaten wurden auch vier Peptidomimetika synthetisierten. Hierfür wurde, basierend auf den Interaktionen zwischen dem LIR-Motiv und der LC3 Proteinoberfläche, ein Pharmakophor-Modell erstellt. Neben einem Pentapeptid wurden auch drei Verbindungen dargestellt, die ein 5-Amino 2-methoxybenzohydrazid-Gerüst besitzen. Um die synthetisierten Verbindungen auf ihre inhibitorische Aktivität auf LC3A bzw. LC3B gegenüber dem LIR-Motiv von p62 hin untersuchen zu können, wurde ein HTRF-basierter Verdrängungsassay entwickelt. Dabei diente ein mit dem LIR-Motiv modifiziertes sGFP als FRET-Akzeptor, während das jeweilige Terbium-Kryptat-gelabelte SNAP-LC3-Fusionsprotein als FRET-Donor fungierte. Neben den Titrationsexperimenten zur Bestimmung der IC50-Werte wurden auch die jeweiligen Dissoziationskonstanten (Kd) von LC3A und LC3B gegenüber dem LIR-sGFP-Fusionsprotein bestimmt, um die IC50-Werte in inhibitorische Konstanten (Ki) zu überführen, da diese untereinander besser vergleichbar sind.
Die Verbindung MH209 zeigte die höchste Aktivität auf LC3A bzw. LC3B und besitzt aufgrund der Noviose-Einheit eine gute Wasserlöslichkeit, weshalb sie für die weiteren Untersuchungen ausgewählt wurde. Im Zuge von Kristallisationsexperimenten gelang die Isolierung und Vermessung eines Co-Kristalls von LC3A mit Verbindung MH209. Durch die Kristallstruktur wurden wichtige Einblicke in die intermolekularen Wechselwirkungen der 4-Hydroxycoumarine mit der LC3A- bzw. LC3B-Proteinoberfläche gewonnen und die Bindungsmode aufgeklärt. Diese Erkenntnisse passen gut zu den Ergebnissen aus den durchgeführten TSA-, ITC- und HTRF-Assays, wie beispielsweise der korrekten Konstitution der Amidbindung am C3 des Coumarin-Gerüstes. Mittels ITC wurde die Verbindung MH209 auf ihre Bindungsaffinität gegenüber den anderen humanen Homologen der Atg8-Proteinfamilie hin untersucht. Dabei zeigte sich, dass MH209 abgesehen von LC3A und LC3B keinerlei Aktivität auf den humanen Atg8-Homologen besitzt. Diese Selektivität ist nützlich, um die biologische Bedeutung der Diversität von Atg8-Homologen in höheren Eukaryonten zu untersuchen und Prozesse, in die diese involviert sind, aufzuklären.
Human protein kinases play essential roles in cellular signaling pathways and - if deregulated - are linked to a large diversity of diseases such as cancer and inflammation or to metabolic diseases. Because of their key role in disease development or progression, kinases have developed into major drug targets resulting in the approval of 52 kinase inhibitors by the Food and Drug Administration (FDA) so far.
Within the drug discovery process, the affinity of the inhibitors is the parameter that is used most often to predict the later efficacy in humans. However, the kinetics of binding have recently emerged as an important but largely neglected factor of kinase inhibitor efficacy. To efficiently suppress a signaling pathway, the targeted kinase needs to be continuously inhibited. Thus, it has been hypothesized that fast binding on-rates and slow off-rates would be the preferred property of an efficacious inhibitor. Despite optimizing the potency of kinase inhibitors, in the past decade optimization of kinetic selectivity has therefore gained interest as a molecule cannot be active unless it is bound, as Paul Ehrlich once stated. There is increasing evidence of correlations between prolonged drug-target residence time and increased drug efficacy, and that inhibitor selectivity in cellular contexts can be modulated by altered residence times. In order to contribute to the understanding of the effect of long residence times on cellular targets we initiated two projects.
The first of these projects is related to the STE20 kinase Serine/threonine kinase 10 (STK10) and its close relative STE20 like kinase (SLK) which have been reported to be frequent off-targets for kinase inhibitors used in the clinics. Also, an inhibition of STK10 and SLK has been linked to a common side-effect of severe skin rash developed upon treatment with the EGFR inhibitor erlotinib, but not gefitinib and the severity of this rash correlated with the treatment outcome, which fits the known biology of STK10 and SLK to be regulators of lymphocyte migration and PLK kinases. However, there are yet no explanations why these two proteins show such high hit-rates across the kinome among the kinase inhibitors. Using structural analysis, we identified the flexibility of STK10 to be the main reason for this hit-rate. The observed strong in vitro potencies did however not translate to the cellular system which is why we investigated the inhibitors residence time on STK10. We found the same flexibility to be the main reason for slow residence times among several inhibitors. We observed large rearrangements in the hydrophobic backpocket of STK10 including the αC, the P-loop enclosing the inhibitor like a lid and strong π-π-stackings to be the main reasons for prolonged residence times on STK10. Interestingly, we observed an increased residence time for erlotinib, which showed skin-related side-effects, giving rise whether the binding kinetics should be investigated for weak cellular off-target effects in future drug discovery efforts.
In the second project we initiated, we illuminate a structural mechanism that allows kinetic selection between two closely related kinases, focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2). Using an inhibitor series designed to probe the mechanism, residence times measured in vitro and in cells showed a strong correlation. Crystal structures and mutagenesis identified hydrophobic interactions with L567, adjacent to the DFG-motif, as being crucial to kinetic selectivity of FAK over PYK2. This specific interaction was observed only when the DFG-motif was stabilized into a helical conformation upon ligand binding to FAK. The interplay between the protein structural mobility and ligand-induced effect was found to be the key regulator of kinetic inhibitor selectivity for FAK over PYK2.
These two projects showed that the parameter residence time should be considered for different problems among the drug discovery process. First, in an open in vivo system not only the potency of a drug alone, but as well its residence time might be of importance. Here we showed that the weak cellular potency translated to prolonged residence times for several inhibitors in cells and established a link between the phenotypic outcome of skin rash after erlotinib treatment and the residence time of this inhibitor on STK10 in cells. On the other hand, medicinal chemistry efforts should consider structure kinetic relationships (SKR) in the optimization process and aim to understand the molecular basis for prolonged target residence times. Here, we showed that a hydrophobic interaction that is enforced upon inhibitor binding is crucial for an unusual helical DFG conformation which arrests the inhibitor and prolongs its residence time providing the molecular basis for understanding the kinetic selectivity of two closely related protein kinases. Establishing the SKRs will help medicinal chemists to kinetically optimize their drug candidates to select a suitable molecule to proceed into further optimization programs. Hence, the projects showed that the target residence time parameter needs to be considered both as a molecular optimization parameter to improve compound potency and binding behavior as well as a parameter to be understood for proceeding to the open system of in vivo models to later modulate the in vivo efficacy of protein kinase targeting drugs.
Bioactive small molecules are used in many research areas as important tools to uncover biological pathways, interpret phenotypic changes, deconvolute protein functions and explore new therapeutic strategies in disease relevant cellular model systems. To unlock the full potential of these small molecules and to ensure reliability of results obtained in cellular assays, it is crucial to understand the properties of these small molecules. These properties encompass their activity and potency on their designated target(s), their selectivity towards unintended off-targets and their phenotypic effects in a cellular system. Approved drugs often engage with multiple targets, which can be beneficial for some applications such as treatment of cancer where several pathways need to be inhibited for treatment efficacy. However, targeting multiple key proteins in diverse pathways also increases the possibility for unspecific or unwanted side effects. For many drugs the entire target space that they modulate is not known. This makes it difficult to use these drugs for target deconvolution or functional assays with the aim to understand the underlying biological processes. In contrast to drugs, for mechanistic studies, a good alternative are chemical tool compounds so called chemical probes that are usually exclusively selective as well as chemogenomic compounds, that inhibit several targets but have narrow selectivity profiles. Because they are mechanistic tools, chemical tool compounds must meet stringent quality criteria and they are therefore well characterized in terms of their potency, selectivity and cellular on-target activity. To ensure that an observed phenotypic effect caused by a compound can be attributed to the described target(s), it is essential to study also properties of chemical tools leading to unspecific cellular effects. There are a variety of unspecific effects that can be caused by physiochemical compound properties that can interfere with phenotypic assays as well as functional compound evaluations. One of these effects is low solubility causing toxicity or intrinsic fluorescence potentially interfering with assay readouts. But unanticipated cellular responses can also arise from unspecific binding, accumulation in cellular compartments or damage caused to organelles such as mitochondria or the cytoskeleton that can result in the induction of diverse forms of cell death.
In this study, we investigated the influence of a variety of small molecules on distinct cell states, by establishing and validating high-content imaging assays, which we called Multiplex assay. This assay portfolio enabled us to detect different cellular responses using diverse fluorescent reporters, such as the influence of a compound on cell viability, induction of cell death programs and modulation of the cell cycle. Additionally, general compound properties such as precipitation and intrinsic fluorescence were simultaneously detected. The assay is adaptable to assess other cellular properties of interest, such as mitochondrial health, changes in cytoskeletal morphology or phospholipidosis. A significant advantage of the assay is that we are using live cells, so we can capture dynamic cellular changes and fluctuations that can be crucial for the understanding of cellular responses.